Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer-induced blindness

C E Thirkill1

  • 1University of California, Davis, Sacramento 95816, USA.

Lung Cancer (Amsterdam, Netherlands)
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Cancer can cause vision loss through paraneoplastic retinopathy. Autoantibodies targeting photoreceptor proteins in the eye, linked to small cell lung cancer, explain this autoimmune response and subsequent blindness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paraneoplastic vitelliform retinopathy secondary to metastatic melanoma.

Klinische Monatsblatter fur Augenheilkunde·2015
Same author

An unusual case of melanoma-associated retinopathy.

Ocular immunology and inflammation·2012
Same author

Immune-mediated paraneoplasia.

British journal of biomedical science·2007
Same author

Autoimmune retinopathy associated with intravesical BCG therapy.

The British journal of ophthalmology·2005
Same author

Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV.

The British journal of dermatology·2005
Same author

Cachexia and poor night vision.

Lancet (London, England)·2004
Same journal

ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410].

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Prognostic impact of the 9th vs 8th TNM classification in small-cell lung cancer. a population-based study.

Lung cancer (Amsterdam, Netherlands)·2026
See all related articles

Area of Science:

  • Ophthalmology
  • Oncology
  • Immunology

Background:

  • Vision loss in cancer patients, particularly with small cell lung cancer (SCCL), has been observed.
  • The link between cancer and retinal deterioration was recognized, but the underlying mechanisms remained unclear.
  • Paraneoplastic retinopathy is associated with cancer, involving immune responses against retinal components.

Purpose of the Study:

  • To elucidate the molecular basis of paraneoplastic retinopathy in cancer patients.
  • To investigate the role of autoantibodies in cancer-associated vision loss.
  • To establish a link between specific cancers and autoimmune reactions in the retina.

Main Methods:

  • Identification of autoantibodies in patients with paraneoplastic retinopathy.

Related Experiment Videos

  • Analysis of autoantibody reactivity against specific photoreceptor proteins.
  • Examination of small cell lung cancer (SCCL) cell cultures for expression of retinal autoantigens.

    • Main Results:

    • A subset of paraneoplastic retinopathy patients produced autoantibodies targeting a single photoreceptor protein.
    • Small cell lung cancer (SCCL) cultures were found to express the same retinal autoantigen.
    • This provided molecular evidence for cancer-induced autoimmune retinopathy.

    Conclusions:

    • Cancer can trigger autoimmune retinopathy through the expression of retinal autoantigens.
    • Autoantibodies against photoreceptor proteins are a key factor in vision loss in some cancer patients.
    • This research defines a molecular basis for cancer-induced blindness via autoimmune mechanisms.